Who Exports Valacyclovir from India — 113 Suppliers Behind a $93.2M Market
India's valacyclovir export market is supplied by 113 active exporters who collectively shipped $93.2M across 2,537 shipments. MYLAN LABORATORIES LIMITED leads with a 49.8% market share, followed by HETERO LABS LIMITED and AUROBINDO PHARMA LTD. The top 5 suppliers together control 97.3% of total export value, reflecting a concentrated market structure.
Top Valacyclovir Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading valacyclovir exporter from India, holding a 49.8% share of the $93.2M market across 2,537 shipments from 113 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, HETERO LABS LIMITED, AUROBINDO PHARMA LTD, V S INTERNATIONAL PRIVATE LIMITED, AUROBINDO PHARMA LIMITED — collectively control 97.3% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (49.8%), HETERO LABS LIMITED (36.4%), AUROBINDO PHARMA LTD (8.7%), V S INTERNATIONAL PRIVATE LIMITED (1.4%), AUROBINDO PHARMA LIMITED (1.0%).
Top Valacyclovir Exporters from India
Ranked by export value · 113 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $46.4M | 3 | 49.8% |
| 2 | HETERO LABS LIMITED VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $33.9M | 12 | 36.4% |
| 3 | AUROBINDO PHARMA LTD VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $8.1M | 2 | 8.7% |
| 4 | V S INTERNATIONAL PRIVATE LIMITED HARMLESS MEDICINES, VALACYCLOVIR MYLAN 500 MG 42BL TABMYLAN VALACYCLOVIR 500 MG 100 BT TAB PACVALACICLOVIR TABLETS 500 MG 100'S | $1.3M | 1 | 1.4% |
| 5 | AUROBINDO PHARMA LIMITED VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $935.5K | 2 | 1.0% |
| 6 | CIPLA LIMITED VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $455.8K | 2 | 0.5% |
| 7 | JUBILANT GENERICS LIMITED VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $303.2K | 2 | 0.3% |
| 8 | JUBILANT GENERICS LTD VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $287.8K | 1 | 0.3% |
| 9 | SERENA PHARMA PRIVATE LIMITED | $287.3K | 1 | 0.3% |
| 10 | SAVA HEALTHCARE LIMITED | $243.8K | 2 | 0.3% |
| 11 | DERRIC WOOD VALCIVIR 1MG TABLETS INV.QTY.9865 PACK 5X3'S=147975 NOSVALCIVIR 500 TABLETS INV.QTY.9940 PACK 5X3'S=149100 NOSVALOVIR VALACYCLOVIR TABLET | $199.4K | 2 | 0.2% |
| 12 | GMSANJIVANI LLP HARMLESS MEDICINES, VALACYCLOVIR MYLAN 500 MG 42BL TABVALCIVIR 1MG TABLETS INV.QTY.9865 PACK 5X3'S=147975 NOSVALACYCLOVIR MYLAN 500 MG 42BL TAB PACKS10272 | $123.5K | 4 | 0.1% |
| 13 | NORTHERN LIFELINE VALOVIR VALACYCLOVIR TABLETVALCIVIR 1MG TABLETS INV.QTY.9865 PACK 5X3'S=147975 NOSVALCIVIR 500 TABLETS INV.QTY.9940 PACK 5X3'S=149100 NOS | $83.6K | 3 | 0.1% |
| 14 | LOTUS INTERNATIONAL VALCIVIR 1MG TABLETS INV.QTY.9865 PACK 5X3'S=147975 NOSVALCIVIR 500 TABLETS INV.QTY.9940 PACK 5X3'S=149100 NOSVALOVIR VALACYCLOVIR TABLET | $67.8K | 1 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Valacyclovir exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Warning Letter, June 2019 | Yes, as of 2023 | Yes | 70+ | Received FDA warning letter in June 2019 for Pydibhimavaram facility; holds over |
| Cipla Limited | Approved | Yes, as of 2023 | Yes | 45 | Holds 45 approved US ANDAs; no FDA warning letters reported. |
| Unichem Laboratories Limited | Approved | Yes, as of 2023 | Yes | 45 | Holds 45 approved US ANDAs; no FDA warning letters reported. |
| Laurus Labs Limited | Approved | Yes, as of 2023 | Yes | Not specified | Manufacturing units approved by USFDA, WHO, and EU authorities; no FDA warning l |
| Micro Labs Limited | Approved | Yes, as of 2023 | Yes | Not specified | Operates 14 GMP-compliant manufacturing plants; no FDA warning letters reported. |
| Viatris (formerly Mylan Laboratories Limited) | Approved | Yes, as of 2023 | Yes | Not specified | WHO GMP certified; no FDA warning letters reported. |
TransData Nexus reviewed the regulatory standing of 6 leading Valacyclovir exporters from India. 5 hold US FDA facility approvals, 6 maintain WHO-GMP certification, and 6 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Valacyclovir sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma City of India," is a pivotal hub for bulk drug production. The city contributes nearly 40% of the country's bulk drug output and hosts over 2,000 pharmaceutical companies. Notably, Hyderabad Pharma City is transforming the region into a global center for pharmaceutical manufacturing and biotechnology research. This concentration of bulk drug manufacturers makes Hyderabad a critical node in the supply chain for active pharmaceutical ingredients (APIs) like Valacyclovir.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat leads India with a 33% share in drug manufacturing and a 28% share in drug exports. The region is home to 130 USFDA-certified drug manufacturing facilities, with major companies like Alembic Pharmaceuticals and Cadila Healthcare operating in Vadodara. This specialization in formulations positions the cluster as a key player in producing finished dosage forms of medications, including Valacyclovir.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a significant export gateway for pharmaceutical products. Mumbai's strategic location and well-established port facilities facilitate the export of pharmaceuticals to global markets. The region hosts numerous pharmaceutical companies that leverage this infrastructure to distribute products like Valacyclovir efficiently.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a pharmaceutical manufacturing hub, primarily due to favorable tax incentives. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units, contributing to the production of various drugs, including generics.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 97.3% of Valacyclovir shipments, it's advisable to diversify the supplier base to mitigate risks associated with over-reliance on a few sources.
- Leverage Hyderabad for API Procurement: Utilize Hyderabad's extensive bulk drug manufacturing capabilities to source high-quality APIs for Valacyclovir production.
- Engage with Gujarat for Formulations: Collaborate with manufacturers in the Ahmedabad-Vadodara region to access expertise in pharmaceutical formulations, ensuring high-quality finished products.
- Optimize Logistics via Mumbai: Utilize the Mumbai-Thane-Raigad corridor's export infrastructure to streamline the distribution of Valacyclovir to international markets.
By strategically engaging with these pharmaceutical clusters, companies can enhance the efficiency and resilience of their Valacyclovir supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Valacyclovir exporters from India
AUROBINDO PHARMA LIMITED — Aurobindo Pharma acquires Khandelwal Labs' non-oncology business for ₹3,250 crore
Aurobindo Pharma's subsidiary, Auro Pharma Limited, acquired the non-oncology prescription formulations business of Khandelwal Laboratories Private Limited. The acquisition includes 23 brands across 67 SKUs and nine pipeline products, primarily in anti-infectives and pain management. The transaction was executed on a going-concern basis through a Business Transfer Agreement. - IMPACT: This acquisition is expected to strengthen Aurobindo Pharma's domestic market presence, potentially enhancing its Valacyclovir export capabilities.
Impact: This acquisition is expected to strengthen Aurobindo Pharma's domestic market presence, potentially enhancing its Valacyclovir export capabilities.
MYLAN LABORATORIES LIMITED (now part of Viatris) — MPP signs sublicences with Mylan to produce generic HIV prevention medicine
The Medicines Patent Pool (MPP) signed sublicence agreements with Mylan to manufacture generic versions of ViiV Healthcare’s long-acting HIV prevention medicine, cabotegravir LA for PrEP. This agreement aims to enable access to this innovative prevention medicine in areas most impacted by HIV. - IMPACT: While this collaboration focuses on HIV prevention, it demonstrates Mylan's commitment to expanding its generic pharmaceutical portfolio, which may indirectly influence its Valacyclovir production and export strategies.
Impact: While this collaboration focuses on HIV prevention, it demonstrates Mylan's commitment to expanding its generic pharmaceutical portfolio, which may indirectly influence its Valacyclovir production and export strategies.
MYLAN LABORATORIES LIMITED — Mylan merges with Upjohn to form Viatris
Mylan N.V. merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. This strategic move aimed to create a new global pharmaceutical company with a diverse portfolio of generic and specialty medicines. - IMPACT: The formation of Viatris may lead to enhanced operational efficiencies and expanded market reach, potentially impacting the production and export of Valacyclovir.
Impact: The formation of Viatris may lead to enhanced operational efficiencies and expanded market reach, potentially impacting the production and export of Valacyclovir.
Common Questions — Valacyclovir Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which valacyclovir supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 62 recorded shipments worth $46.4M. HETERO LABS LIMITED (251 shipments) and AUROBINDO PHARMA LTD (41 shipments) are also established high-volume exporters.
Q How many valacyclovir manufacturers are there in India?
India has 113 active valacyclovir exporters with a combined export market of $93.2M across 2,537 shipments to 70 countries. The top 5 suppliers hold 97.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for valacyclovir from India?
Average FOB unit price: $3.32 per unit, ranging from $0.01 to $251.00. Average shipment value: $36.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 113 verified Indian exporters of Valacyclovir ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,537 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 70 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,537 Verified Shipments
113 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists